Coherus Bioscien Stock Price, News & Analysis

Coherus BioSciences (NASDAQ: CHRS) has announced a clinical collaboration with STORM Therapeutics to evaluate the combination of STC-15 (a METTL3 inhibitor) with LOQTORZI (toripalimab-tpzi), their next-generation PD-1 inhibitor. The first patient has been dosed in a Phase 1b/2 study targeting multiple cancer types including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, and endometrial cancer.

The study will enroll up to 188 patients in the United States, with Phase 1b focusing on safety and efficacy of the combination, followed by Phase 2 expansion cohorts. Under the agreement, Coherus will supply LOQTORZI while STORM will sponsor the trial, with both companies retaining commercial rights to their respective compounds.

Coherus BioSciences (CHRS) reported Q1 2025 financial results, highlighting its strategic transformation to innovative oncology. LOQTORZI generated net revenue of $7.3 million with >15% patient demand growth vs Q4 2024. The company completed the UDENYCA divestiture for up to $558.4 million, receiving $483.4 million upfront. Q1 results showed net loss from continuing operations of $47.4 million ($0.41/share). Key pipeline developments include positive Phase 1b data for CHS-114 in head and neck cancer and ongoing trials for casdozokitug combination therapy. Cash position was $82.4 million as of March 31, 2025. The company is advancing its oncology portfolio with LOQTORZI, the only FDA-approved treatment for nasopharyngeal carcinoma, while progressing clinical trials for CHS-114 and casdozokitug with data readouts expected in 2026.

Coherus BioSciences (NASDAQ: CHRS) has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. EDT on the same day, where management will discuss the financial results and provide a business update. Investors can pre-register for the conference call to receive dial-in information and a personal PIN. A webcast will be available live and archived on the company's investor relations website. The Q1 2025 financial results press release and related materials will be accessible at https://investors.coherus.com before the conference call.

Coherus BioSciences (NASDAQ: CHRS) has announced its participation in four upcoming investor conferences in May and June 2025:

• Citizens Life Science Conference (May 8, NY)
• HCW BioConnect @ Nasdaq NYC 2025 (May 20, NY)
• TD Cowen 6th Annual Oncology Innovation Summit (May 27, Virtual)
• Jefferies Global Healthcare Conference (June 4, NY)

All presentations will be accessible via webcasts through the company's investor relations website, with replays available for 30 days. One-on-one meetings with management can be arranged through respective bank representatives.

Coherus BioSciences (NASDAQ: CHRS) presented promising Phase 1 clinical trial data for CHS-114, their selective anti-CCR8 antibody, in combination with toripalimab for head and neck squamous cell carcinoma (HNSCC) treatment at AACR 2025.

Key findings include:

• Confirmed partial response in a heavily pretreated PD-1 refractory patient
• >50% depletion in CCR8+ Treg cells
• Significant increase in CD8+ T cells
• Manageable safety profile consistent with advanced disease

The study evaluated CHS-114 as monotherapy and in combination with toripalimab in 21 patients with advanced solid tumors. A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing, with results expected in first half of 2026.

Coherus BioSciences (NASDAQ: CHRS) has completed the divestiture of its UDENYCA® franchise to Intas Pharmaceuticals in a deal valued at up to $558.4 million. The transaction includes an upfront payment of $483.4 million (with $118.4 million for UDENYCA inventory) and potential milestone payments of up to $75 million.

The deal provides Coherus with a $250 million post-close cash balance, extending runway into 2027. The company will now focus exclusively on innovative oncology programs including:

• LOQTORZI® - a revenue-generating PD-1 inhibitor
• Casdozokitug - a first-in-class IL-27 antagonist
• CHS-114 - a selective CCR8 antibody

The transaction closed on April 11, 2025, with Accord BioPharma, Intas' U.S. specialty division, assuming full responsibility for the UDENYCA franchise in the U.S.

Coherus BioSciences (NASDAQ: CHRS) has announced plans to repurchase approximately $170 million of its 1.500% Convertible Senior Subordinated Notes due 2026 through privately negotiated transactions. The repurchase will be executed at 100% of principal amount plus accrued interest.

The repurchase is contingent on the closing of the previously announced UDENYCA franchise divestiture to Intas Pharmaceuticals Following this initial repurchase, about $60 million in convertible notes will remain outstanding, which Coherus intends to repurchase after the transaction closes.

Additionally, holders representing a majority of the outstanding notes have agreed to provide consent for amendments to the indenture, allowing the UDENYCA divestiture to proceed.

Coherus BioSciences (NASDAQ: CHRS) has announced the upcoming presentation of interim data from its ongoing Phase 1 clinical trial of CHS-114, a selective, cytolytic anti-CCR8 antibody, at the 2025 AACR Annual Meeting. The study evaluates CHS-114 both as a monotherapy and in combination with toripalimab for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

The presentation, led by Dr. Francis Worden from the University of Michigan, will be featured as a poster (Abstract #CT038) in the Phase 0 and Phase 1 Clinical Trials section. The session is scheduled for Monday, April 28, 2025, from 9:00 a.m. to 12:00 p.m. CDT at McCormick Place Convention Center in Chicago.

Coherus BioSciences (CHRS) reported its Q4 and full year 2024 results, with annual net revenue increasing 4% to $267.0 million. The company's transformation highlights include strong performance of key products: UDENYCA® net revenue grew 62% year-over-year, while LOQTORZI® sales increased 29% quarter-over-quarter.

A significant development is the planned UDENYCA divestiture for up to $558.4 million, expected to close in late Q1 or early Q2 2025. Post-divestiture, Coherus projects approximately $250 million in cash, providing a runway exceeding two years. The company plans to reduce headcount by 30% to about 155 employees.

The company's focus shifts to oncology, with LOQTORZI receiving preferred status in NCCN guidelines for nasopharyngeal carcinoma treatment. Multiple clinical data readouts are expected across their oncology pipeline in 2025/2026, including developments in casdozokitug and CHS-114 programs.